Evolocumab Leads PCSK9 Race In Europe With Positive CHMP Opinion
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s PCSK9 inhibitor looks set to be the first in a new generation of lipid-lowering agents to reach European markets after it received a positive opinion from Europe’s top scientific advisory panel.